You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model
|
|---|---|
| Published in |
BMC Public Health, February 2017
|
| DOI | 10.1186/s12889-017-4064-7 |
| Pubmed ID | |
| Authors |
Ariel Esteban Bardach, Osvaldo Ulises Garay, María Calderón, Andrés Pichón-Riviére, Federico Augustovski, Sebastián García Martí, Paula Cortiñas, Marino Gonzalez, Laura T. Naranjo, Jorge Alberto Gomez, Joaquín Enzo Caporale |
| Abstract |
Cervical cancer (CC) and genital warts (GW) are a significant public health issue in Venezuela. Our objective was to assess the cost-effectiveness of the two available vaccines, bivalent and quadrivalent, against Human Papillomavirus (HPV) in Venezuelan girls in order to inform decision-makers. A previously published Markov cohort model, informed by the best available evidence, was adapted to the Venezuelan context to evaluate the effects of vaccination on health and healthcare costs from the perspective of the healthcare payer in an 11-year-old girls cohort of 264,489. Costs and quality-adjusted life years (QALYs) were discounted at 5%. Eight scenarios were analyzed to depict the cost-effectiveness under alternative vaccine prices, exchange rates and dosing schemes. Deterministic and probabilistic sensitivity analyses were performed. Compared to screening only, the bivalent and quadrivalent vaccines were cost-saving in all scenarios, avoiding 2,310 and 2,143 deaths, 4,781 and 4,431 CCs up to 18,459 GW for the quadrivalent vaccine and gaining 4,486 and 4,395 discounted QALYs respectively. For both vaccines, the main determinants of variations in the incremental costs-effectiveness ratio after running deterministic and probabilistic sensitivity analyses were transition probabilities, vaccine and cancer-treatment costs and HPV 16 and 18 distribution in CC cases. When comparing vaccines, none of them was consistently more cost-effective than the other. In sensitivity analyses, for these comparisons, the main determinants were GW incidence, the level of cross-protection and, for some scenarios, vaccines costs. Immunization with the bivalent or quadrivalent HPV vaccines showed to be cost-saving or cost-effective in Venezuela, falling below the threshold of one Gross Domestic Product (GDP) per capita (104,404 VEF) per QALY gained. Deterministic and probabilistic sensitivity analyses confirmed the robustness of these results. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 33% |
| Colombia | 1 | 33% |
| Argentina | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Unknown | 104 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 20 | 19% |
| Researcher | 15 | 14% |
| Student > Doctoral Student | 9 | 9% |
| Student > Bachelor | 7 | 7% |
| Student > Ph. D. Student | 6 | 6% |
| Other | 18 | 17% |
| Unknown | 30 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 20% |
| Nursing and Health Professions | 11 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 10% |
| Economics, Econometrics and Finance | 8 | 8% |
| Business, Management and Accounting | 5 | 5% |
| Other | 18 | 17% |
| Unknown | 32 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 April 2017.
All research outputs
#13,538,247
of 22,953,506 outputs
Outputs from BMC Public Health
#9,605
of 14,958 outputs
Outputs of similar age
#211,802
of 420,315 outputs
Outputs of similar age from BMC Public Health
#147
of 207 outputs
Altmetric has tracked 22,953,506 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 14,958 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.9. This one is in the 33rd percentile – i.e., 33% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 420,315 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 207 others from the same source and published within six weeks on either side of this one. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.